This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wiener, J. R. Articles by Gallick, G. E. Search for Related Content PubMed PubMed Citation Articles by Wiener, J. R. Articles by Gallick, G. E.

Decreased Src Tyrosine Kinase Activity Inhibits Malignant Human Ovarian Cancer Tumor Growth in a Nude Mouse Model¹

Departments of Molecular Oncology [J. R. W., R. P. K.], Cancer Biology [K. N., C. D. B., G. E. G.], and Clinical Investigation [R. C. B.], University of Texas, M. D. Anderson Cancer Center, Houston, Texas 77030

The Src protein tyrosine kinase is overexpressed and activated in a number of human cancers, including some human ovarian cancers. To determine whether Src activity plays a role in ovarian tumor growth, stable derivatives of the SKOv-3 human ovarian cancer cell line that exhibited reduced Src tyrosine kinase activity were generated by transfection with an antisense c-src construct. Comparison of these cell lines with parental SKOv-3 cells and stable sense c-src vector-transfected control lines revealed no phenotypic alterations in anchorage-dependent proliferation, adherence, density saturation, or wound migration. However, reduction in Src activity was associated with altered cellular morphology, dramatically reduced anchorage-independent growth, and, when assessed for tumor development in a xenograft nude mouse model, diminished tumor growth. Furthermore, reduction of Src activity in the antisense c-src cell lines was associated with reduced vascular endothelial growth factor mRNA expression in vitro, and tumors derived from these cell lines displayed a phenotype indicative of abortive microvessel vascularization. These results strongly suggest that Src is involved in critical oncogenic pathways that modulate tumor growth from this ovarian cell line. Furthermore, this evidence suggests that as in other tumor systems, Src activity is required for vascular endothelial growth factor induction and angiogenic development.

This article has been cited by other articles:

				E. L.-H. Leung, I. Y.-S. Tam, V. P.-C. Tin, D. T.-T. Chua, A. D.-L. Sihoe, L.-C. Cheng, J. C.-M. Ho, L.-P. Chung, and M. P. Wong Src Promotes Survival and Invasion of Lung Cancers with Epidermal Growth Factor Receptor Abnormalities and Is a Potential Candidate for Molecular-Targeted Therapy Mol. Cancer Res., June 1, 2009; 7(6): 923 - 932. [Abstract] [Full Text] [PDF]

				C. N. Landen Jr., C. Lu, L. Y. Han, K. T. Coffman, E. Bruckheimer, J. Halder, L. S. Mangala, W. M. Merritt, Y. G. Lin, C. Gao, et al. Efficacy and Antivascular Effects of EphA2 Reduction With an Agonistic Antibody in Ovarian Cancer. J Natl Cancer Inst, November 1, 2006; 98(21): 1558 - 1570. [Abstract] [Full Text] [PDF]

				L. Y. Han, C. N. Landen, J. G. Trevino, J. Halder, Y. G. Lin, A. A. Kamat, T.-J. Kim, W. M. Merritt, R. L. Coleman, D. M. Gershenson, et al. Antiangiogenic and Antitumor Effects of Src Inhibition in Ovarian Carcinoma. Cancer Res., September 1, 2006; 66(17): 8633 - 8639. [Abstract] [Full Text] [PDF]

				J. M. Golas, J. Lucas, C. Etienne, J. Golas, C. Discafani, L. Sridharan, E. Boghaert, K. Arndt, F. Ye, D. H. Boschelli, et al. SKI-606, a Src/Abl Inhibitor with In vivo Activity in Colon Tumor Xenograft Models Cancer Res., June 15, 2005; 65(12): 5358 - 5364. [Abstract] [Full Text] [PDF]

				M. S. Duxbury, H. Ito, M. J. Zinner, S. W. Ashley, and E. E. Whang Inhibition of Src Tyrosine Kinase Impairs Inherent and Acquired Gemcitabine Resistance in Human Pancreatic Adenocarcinoma Cells Clin. Cancer Res., April 1, 2004; 10(7): 2307 - 2318. [Abstract] [Full Text] [PDF]

				L. Zhang, N. Yang, J.-R. Conejo Garcia, A. Mohamed, F. Benencia, S. C. Rubin, D. Allman, and G. Coukos Generation of a Syngeneic Mouse Model to Study the Effects of Vascular Endothelial Growth Factor in Ovarian Carcinoma Am. J. Pathol., December 1, 2002; 161(6): 2295 - 2309. [Abstract] [Full Text] [PDF]

				J.-S. Nam, Y. Ino, M. Sakamoto, and S. Hirohashi Src Family Kinase Inhibitor PP2 Restores the E-Cadherin/Catenin Cell Adhesion System in Human Cancer Cells and Reduces Cancer Metastasis Clin. Cancer Res., July 1, 2002; 8(7): 2430 - 2436. [Abstract] [Full Text] [PDF]

				S. Pal, K. Datta, and D. Mukhopadhyay Central Role of p53 on Regulation of Vascular Permeability Factor/Vascular Endothelial Growth Factor (VPF/VEGF) Expression in Mammary Carcinoma Cancer Res., September 1, 2001; 61(18): 6952 - 6957. [Abstract] [Full Text] [PDF]

				K. Bonham, S. A. Ritchie, S. M. Dehm, K. Snyder, and F. M. Boyd An Alternative, Human SRC Promoter and Its Regulation by Hepatic Nuclear Factor-1alpha J. Biol. Chem., November 22, 2000; 275(48): 37604 - 37611. [Abstract] [Full Text] [PDF]